Trial Information

Selection of Young Patients (< 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study.

Treatment with rituximab and chemotherapy (R-CHOP)is the accepted treatment for young
patients with diffuse large B cell Non-Hodgkin's Lymphoma. However not every patient
benefits with this expensive therapy. Recent data suggest that patients with BCL-6 negative
lymphoma are more sensitive to Rituximab therapy. It is also known that patients with
high-intermediate and high IPI risk does not benefit form standard three weekly CHOP
chemotherapy.

In this study we intend to define a subgroup of patients in whom this therapy will be of
maximum benefit.

We will prospectively treat a group of patients with the following characteristics:

< 60 years old low and low intermediate IPI risk BCL-6 negative B-cell NHL Treatment
regimen: R-CHOP (standard dosis) for 8 cycles